IL131217D0 - Novel methods and compositions for delivery of taxanes - Google Patents

Novel methods and compositions for delivery of taxanes

Info

Publication number
IL131217D0
IL131217D0 IL13121798A IL13121798A IL131217D0 IL 131217 D0 IL131217 D0 IL 131217D0 IL 13121798 A IL13121798 A IL 13121798A IL 13121798 A IL13121798 A IL 13121798A IL 131217 D0 IL131217 D0 IL 131217D0
Authority
IL
Israel
Prior art keywords
taxanes
delivery
compositions
novel methods
novel
Prior art date
Application number
IL13121798A
Original Assignee
Napro Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Application filed by Napro Biotherapeutics Inc filed Critical Napro Biotherapeutics Inc
Priority to US7745998P priority Critical
Priority to PCT/US1999/005151 priority patent/WO1999045918A1/en
Publication of IL131217D0 publication Critical patent/IL131217D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22138176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131217(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
IL13121798A 1998-03-10 1998-03-10 Novel methods and compositions for delivery of taxanes IL131217D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US7745998P true 1998-03-10 1998-03-10
PCT/US1999/005151 WO1999045918A1 (en) 1998-03-10 1999-03-10 Methods and compositions for delivery of taxanes

Publications (1)

Publication Number Publication Date
IL131217D0 true IL131217D0 (en) 2001-01-28

Family

ID=22138176

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13121798A IL131217D0 (en) 1998-03-10 1998-03-10 Novel methods and compositions for delivery of taxanes

Country Status (17)

Country Link
US (1) US20010029264A1 (en)
EP (1) EP0977562B8 (en)
JP (1) JP2001524988A (en)
KR (1) KR20010012363A (en)
CN (1) CN1255852A (en)
AT (1) AT314844T (en)
AU (1) AU762926B2 (en)
BR (1) BR9904856A (en)
CA (1) CA2288240A1 (en)
DE (1) DE69929313T2 (en)
DK (1) DK0977562T3 (en)
ES (1) ES2257038T3 (en)
IL (1) IL131217D0 (en)
MX (1) MX9910340A (en)
PT (1) PT977562E (en)
WO (1) WO1999045918A1 (en)
ZA (1) ZA9901885B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE60111352T2 (en) * 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin compositions
CZ20013498A3 (en) * 2000-02-02 2002-04-17 Florida State University Research Foundation, Inc. Taxane formulations having enhanced solubility
AU3928202A (en) 2000-11-28 2002-06-11 Transform Pharmaceuticals Inc Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
JP2004520398A (en) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニーPharmacia & Upjohn Company Chemotherapy microemulsion compositions of paclitaxel oral bioavailability was improved
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6710195B2 (en) * 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
IL162118D0 (en) * 2001-12-20 2005-11-20 Squibb Bristol Myers Co Pharmaceutical compositions containing an orally active taxane derivative
DE60313299T2 (en) * 2002-03-01 2008-01-03 Novagali Pharma Sa Self-emulsifying systems for relief of taxoids
EP1340497A1 (en) * 2002-03-01 2003-09-03 Novagali Sas Self emulsifying drug delivery systems for poorly soluble drugs
UA82328C2 (en) * 2002-07-30 2008-04-10 Уайт Parenteral formulations of rapamycin hydroxyester (variants) and a method for its preparation
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck A medical device for drug delivery
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20040127551A1 (en) * 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
EP1594459B1 (en) * 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004091506A2 (en) * 2003-04-10 2004-10-28 Ivax Research, Inc. Taxane-based compositions and methods of use
EP1498120A1 (en) * 2003-07-18 2005-01-19 Rhone-Poulenc Rorer S.A. Semi-solid formulations for the oral administration of taxoids
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
EP1713442A1 (en) * 2004-01-30 2006-10-25 Pfizer Italia S.r.l. Semisolid matrix pharmaceutical formulations
WO2005074889A1 (en) * 2004-02-03 2005-08-18 Dinesh Shantilal Patel Novel compositions of taxol derivatives and the process for the manufacture thereof
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
EP1793806A2 (en) * 2004-09-30 2007-06-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
CN101998828A (en) * 2008-03-28 2011-03-30 粒子科学有限公司 Pharmaceutical solutions and method for solubilizing therapeutic agents
CN102000052B (en) 2008-06-25 2012-12-12 重庆市中药研究院 Application of taxol and taxol derivatives to pharmacy
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
MX2013007959A (en) * 2011-01-10 2013-12-06 Celgene Corp Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl] -3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide.
TWI624274B (en) 2012-10-01 2018-05-21 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228162A (en) * 1979-07-09 1980-10-14 Research Corporation Dimethyl isosorbide in liquid formulation of aspirin
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
WO1994012031A1 (en) * 1992-11-27 1994-06-09 Napro Biotherapeutics, Inc. Injectable composition
DE59409377D1 (en) * 1993-10-22 2000-06-29 Hexal Ag derivative pharmaceutical composition with cyclosporin A, a vitamin E and an emulsifier
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs

Also Published As

Publication number Publication date
EP0977562B1 (en) 2006-01-04
BR9904856A (en) 2000-07-18
WO1999045918A1 (en) 1999-09-16
DK0977562T3 (en) 2006-05-01
AT314844T (en) 2006-02-15
US20010029264A1 (en) 2001-10-11
EP0977562A1 (en) 2000-02-09
MX9910340A (en) 2000-04-01
DE69929313D1 (en) 2006-03-30
ZA9901885B (en) 1999-09-10
EP0977562B8 (en) 2006-04-26
DE69929313T2 (en) 2006-08-17
ES2257038T3 (en) 2006-07-16
KR20010012363A (en) 2001-02-15
CN1255852A (en) 2000-06-07
CA2288240A1 (en) 1999-09-16
JP2001524988A (en) 2001-12-04
AU2902299A (en) 1999-09-27
PT977562E (en) 2006-05-31
AU762926B2 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
TW575693B (en) Electroplating composition and method of using
EG24291A (en) Novel form of s-omeprazole
AU757237C (en) Compositions and methods of treating tumors
AP1709A (en) Ethanolate of zithromycin process for manufacture and pharmaceutical compositions thereof
SI1274728T1 (en) Methods and compositions for the prevention and treatment of anemia
PL354923A1 (en) Quinazoline compounds and pharmaceutical compositions containing them
HU0104316A3 (en) Substituted benzopyran analogs for the treatment of inflammation and pharmaceutical compositions containing them
HU9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HU0101804A3 (en) Adjuvant composition and methods for its use
HU9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
ZA9507356B (en) Delivery of solid drug compositions
PL193674B1 (en) Method of selectively deriving taxanes
IL146119A (en) Medicament compositions based on anticholinergically effective compounds and beta-mimetics
AU2001261474A1 (en) Compositions and methods for the treatment of cancer
IL132217A (en) Substained-release compositions and method for preparing same
PT2261335T (en) Compositions and methods for increasing bone mineralisation
PL341372A1 (en) Cellecoxibe containing compositions
HU9901606D0 (en) Pharmaceutical compositions
PT994903E (en) Methods and compositions for galactosiled glicoproteins
HU0104495A3 (en) N-substituted 2-cyanopyrrolidines and pharmaceutical compositions containing them
HU9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
PT1066027E (en) Pharmaceutical composition of topiramato
HU0105021A3 (en) Compositions having improved delivery of actives and process for their preparation
HU0001547A3 (en) Novel form of s-omeprazole
PT945132E (en) Composition of ibupphene